Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial

Karin Due Bruun, Kirstine Amris, Henrik Bjarke Vaegter, Morten Rune Blichfeldt-Eckhardt, Anders Holsgaard-Larsen, Robin Christensen, Palle Toft, Karin Due Bruun, Kirstine Amris, Henrik Bjarke Vaegter, Morten Rune Blichfeldt-Eckhardt, Anders Holsgaard-Larsen, Robin Christensen, Palle Toft

Abstract

Background: Low-dose naltrexone (LDN) is used widely as an off-label treatment for pain despite limited evidence for its effectiveness. A few small trials with a high risk of bias have investigated the effect of LDN on pain associated with fibromyalgia in women, but larger and more methodologically robust studies are needed. The primary aim of this randomized controlled trial is to investigate if 12 weeks of LDN treatment is superior to placebo in reducing the average pain intensity during the last 7 days in women with fibromyalgia.

Methods: A single-center, permuted block randomized, double-blind, placebo-controlled, parallel-group trial will be performed in Denmark. Randomization comprises 100 women aged 18-64 years diagnosed with fibromyalgia who will be treated with either LDN or placebo for 12 weeks including a 4-week titration phase. The primary outcome is change in average pain intensity (during the last 7 days) from baseline to 12 weeks. Secondary outcomes are other fibromyalgia-related symptoms, i.e., tenderness, fatigue, sleep disturbance, stiffness, memory problems, depression, anxiety and measures of global assessment, physical function, impact of fibromyalgia, pain distribution, and health-related quality of life. Intention-to-treat analysis will be performed, and the number of responders with a more than 15%, 30%, and 50% improvement of pain after 12 weeks will be calculated for the LDN and placebo groups. Exploratory outcomes include measures of pain sensitivity, muscle performance, and biomarkers.

Discussion: This study will contribute with high-level evidence on the efficacy of low-dose naltrexone for the treatment of pain in women with fibromyalgia. Secondary outcomes include both disease-specific and generic components investigating whether LDN influences other symptoms than pain. Explorative outcomes are included to provide greater insight into the mechanism of action of LDN and possibly a better understanding of the underlying pathology in fibromyalgia.

Trial registration: EudraCT 2019-000702-30. Registered on 12 July 2019. ClinicalTrials.gov NCT04270877. Registered on 17 February 2020.

Keywords: Fibromyalgia; LDN; Low dose naltrexone; Pain; RCT.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Overview of the participant flow

References

    1. Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn’s disease, and other chronic pain disorders. Pharmacotherapy. 2018;38(3):382–389. doi: 10.1002/phar.2086.
    1. Yoon G, Kim SW, Thuras P, Westermeyer J. Safety, tolerability, and feasibility of high-dose naltrexone in alcohol dependence: an open-label study. Hum Psychopharmacol. 2011;26(2):125–132. doi: 10.1002/hup.1183.
    1. Verebey K. The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics. NIDA Res Monogr. 1981;28:147–158.
    1. Valenta JP, Job MO, Mangieri RA, Schier CJ, Howard EC, Gonzales RA. mu-opioid receptors in the stimulation of mesolimbic dopamine activity by ethanol and morphine in Long-Evans rats: a delayed effect of ethanol. Psychopharmacology (Berl) 2013;228(3):389–400. doi: 10.1007/s00213-013-3041-9.
    1. Crabtree BL. Review of naltrexone, a long-acting opiate antagonist. Clin Pharm. 1984;3(3):273–280.
    1. Gillman MA, Lichtigfeld FJ. A pharmacological overview of opioid mechanisms mediating analgesia and hyperalgesia. Neurol Res. 1985;7(3):106–119. doi: 10.1080/01616412.1985.11739709.
    1. Tempel A, Kessler JA, Zukin RS. Chronic naltrexone treatment increases expression of preproenkephalin and preprotachykinin mRNA in discrete brain regions. J Neurosci. 1990;10(3):741–747. doi: 10.1523/JNEUROSCI.10-03-00741.1990.
    1. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. doi: 10.1007/s10067-014-2517-2.
    1. Loggia ML, Chonde DB, Akeju O, Arabasz G, Catana C, Edwards RR, Hill E, Hsu S, Izquierdo-Garcia D, Ji RR, Riley M, Wasan AD, Zürcher NR, Albrecht DS, Vangel MG, Rosen BR, Napadow V, Hooker JM. Evidence for brain glial activation in chronic pain patients. Brain. 2015;138(Pt 3):604–615. doi: 10.1093/brain/awu377.
    1. Bruno K, Woller SA, Miller YI, Yaksh TL, Wallace M, Beaton G, Chakravarthy K. Targeting toll-like receptor-4 (TLR4)-an emerging therapeutic target for persistent pain states. Pain. 2018;159(10):1908–1915. doi: 10.1097/j.pain.0000000000001306.
    1. Ghai B, Bansal D, Hota D, Shah CS. Off-label, low-dose naltrexone for refractory chronic low back pain. Pain Med. 2014;15(5):883–884. doi: 10.1111/pme.12345.
    1. Hota D, Srinivasan A, Dutta P, Bhansali A, Chakrabarti A. Off-label, low-dose naltrexone for refractory painful diabetic neuropathy. Pain Med. 2016;17(4):790–791. doi: 10.1093/pm/pnv009.
    1. Sturn KM, Collin M. Low-dose naltrexone: a new therapy option for complex regional pain syndrome type I patients. Int J Pharm Compd. 2016;20(3):197–201.
    1. Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663–672. doi: 10.1111/j.1526-4637.2009.00613.x.
    1. Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529–538. doi: 10.1002/art.37734.
    1. Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines. 2017;5(2):16. doi: 10.3390/biomedicines5020016.
    1. Bolton MJ, Chapman BP, Van Marwijk H. Low-dose naltrexone as a treatment for chronic fatigue syndrome. BMJ Case Rep. 2020;13(1):e232502. doi: 10.1136/bcr-2019-232502.
    1. Bruun-Plesner K, Blichfeldt-Eckhardt MR, Vaegter HB, Lauridsen JT, Amris K, Toft P. Low-dose naltrexone for the treatment of fibromyalgia: investigation of dose-response relationships. Pain Med. 2020;21(10):2253–2261. doi: 10.1093/pm/pnaa001.
    1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Fiechtner JJ, Michael Franklin C, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, Mccain GA, John Reynolds W, Romano TJ, Jon Russell I, Sheon RP. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33(2):160–172. doi: 10.1002/art.1780330203.
    1. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613. doi: 10.1046/j.1525-1497.2001.016009606.x.
    1. Mease PJ, Clauw DJ, Christensen R, Crofford LJ, Gendreau RM, Martin SA, et al. Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update. J Rheumatol. 2011;38(7):1487–1495. doi: 10.3899/jrheum.110277.
    1. Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther. 2009;11(4):R120. doi: 10.1186/ar2783.
    1. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Hauser W, Katz RL, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46(3):319–329. doi: 10.1016/j.semarthrit.2016.08.012.
    1. Dworkin RH, Turk DC, McDermott MP, Peirce-Sandner S, Burke LB, Cowan P, et al. Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain. 2009;146(3):238–244. doi: 10.1016/j.pain.2009.08.019.
    1. Devlin NJ, Brooks R. EQ-5D and the EuroQol Group: past, present and future. Applied Health Economics and Health Policy. 2017;15(2):127–137. doi: 10.1007/s40258-017-0310-5.
    1. Bandak E, Amris K, Bliddal H, Danneskiold-Samsoe B, Henriksen M. Muscle fatigue in fibromyalgia is in the brain, not in the muscles: a case-control study of perceived versus objective muscle fatigue. Ann Rheum Dis. 2013;72(6):963–966. doi: 10.1136/annrheumdis-2012-202340.
    1. Martin-Martinez JP, Collado-Mateo D, Dominguez-Munoz FJ, Villafaina S, Gusi N, Perez-Gomez J. Reliability of the 30 s chair stand test in women with fibromyalgia. Int J Environ Res Public Health. 2019;16(13):2344. doi: 10.3390/ijerph16132344.
    1. Detry MA, Ma Y. Analyzing repeated measurements using mixed models. Jama-J Am Med Assoc. 2016;315(4):407–408. doi: 10.1001/jama.2015.19394.
    1. Cao J, Zhang S. Multiple comparison procedures. JAMA. 2014;312(5):543–544. doi: 10.1001/jama.2014.9440.
    1. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001;125(1-2):279–284. doi: 10.1016/S0166-4328(01)00297-2.
    1. Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014;311(15):1547–1555. doi: 10.1001/jama.2014.3266.
    1. Yunus MB. Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Semin Arthritis Rheum. 2008;37(6):339–352. doi: 10.1016/j.semarthrit.2007.09.003.
    1. Gracely RH, Ambrose KR. Neuroimaging of fibromyalgia. Best Pract Res Clin Rheumatol. 2011;25(2):271–284. doi: 10.1016/j.berh.2011.02.003.
    1. Wolfe F, Walitt B, Perrot S, Rasker JJ, Hauser W. Fibromyalgia diagnosis and biased assessment: sex, prevalence and bias. PLoS One. 2018;13(9):e0203755. doi: 10.1371/journal.pone.0203755.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅